Key Takeaways:
Novavax Inc. (NVAX) reported first-quarter revenue of $139.5 million, beating consensus estimates by over $58 million and sending its shares soaring 16 percent.
"The results validate our strategy," John Jacobs, CEO of Novavax, said on the company's earnings call. The company is focusing on expanding partnerships for its Matrix-M adjuvant, a key component in its successful COVID-19 vaccine.
The vaccine maker posted a net loss of $0.06 per share, which was $0.26 better than analysts had forecast. While revenue was down 79 percent year-over-year from the highs of the pandemic, the strong beat on both the top and bottom lines fueled investor optimism.
The stock's double-digit percentage gain reflects growing confidence in Novavax's plan to diversify beyond its COVID-19 vaccine. The company is leveraging its Matrix-M adjuvant technology, with new partnerships aimed at developing new vaccines and treatments for oncology and other infectious diseases. This strategy aims to create new, long-term revenue streams.
Adding to the positive sentiment, a recent patient survey indicated that individuals were twice as likely to choose Novavax's COVID-19 shot again over a competing vaccine from Moderna, suggesting strong brand loyalty.
For its full-year 2026 forecast, Novavax is targeting adjusted revenue between $230 million and $270 million. The company also refined its long-term operating expense goals, aiming for a run-rate of $150 million to $200 million by 2028, signaling a commitment to profitability.
The guidance suggests management is confident in its commercial execution and the potential of its new partnerships. Investors will be watching for further announcements on the company's clinical pipeline progress throughout the year.
This article is for informational purposes only and does not constitute investment advice.
